Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human, Open-label, Phase 1 Dose-Escalation Study of MSB2311, A Humanized Anti-PD-L1 Monoclonal Antibody in Subjects With Advanced Solid Tumors

NCT03463473 is registered in ClinicalTrials.gov with Suzhou Transcenta Therapeutics Co., Ltd. as lead sponsor.

NCT NCT03463473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03463473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human, Open-label, Phase 1 Dose-Escalation Study of MSB2311, A Humanized Anti-PD-L1 Monoclonal Antibody in Subjects With Advanced Solid Tumors
Lead sponsor
Suzhou Transcenta Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
April 12, 2018
Completion date
June 1, 2020
Enrollment
42 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors